Human Recombinant VEGFR3 Extracellular Domain

• Description:

  Human Recombinant VEGFR3 Extracellular Domain _x000D_ Catalog number: B2017052_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: 86 kDa_x000D_ Supplied as: Powder_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -80°C_x000D_ Keywords: FLT4, Fms-like Tyrosine Kinase 4, Tyrosine-protein Kinase Receptor FLT4, Vascular Endothelial Growth Factor Receptor 3_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Ding N, Ruan Y, Fu X, Lin Y, Yu H, Han L, Fu C, Zhang J, Hu X. Improving production of N-glycosylated recombinant proteins by leaky Escherichia coli 3 Biotech. 2019 Aug;9(8):302._x000D_ 2: Leppänen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K. Structural determinants of growth factor binding and specificity by VEGF receptor 2 Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2425-30._x000D_ 3: Thelen A, Scholz A, Benckert C, von Marschall Z, Schröder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma Int J Cancer. 2008 Jun 1;122(11):2471-81._x000D_ 4: Yang Y, Xie P, Opatowsky Y, Schlessinger J. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1906-11._x000D_ 5: Deng Y, Zhang X, Simons M. Molecular controls of lymphatic VEGFR3 signaling Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):421-9._x000D_ 6: Heinolainen K, Karaman S, D'Amico G, Tammela T, Sormunen R, Eklund L, Alitalo K, Zarkada G. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling Circ Res. 2017 Apr 28;120(9):1414-1425._x000D_ 7: Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K, Rockson SG. Therapeutic lymphangiogenesis with human recombinant VEGF-C FASEB J. 2002 Dec;16(14):1985-7._x000D_ 8: Hwang-Bo J, Yoo KH, Park JH, Jeong HS, Chung IS. Recombinant canstatin inhibits angiopoietin-1-induced angiogenesis and lymphangiogenesis Int J Cancer. 2012 Jul 15;131(2):298-309._x000D_ 9: Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, Witte L, Zhu Z. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3 Mol Cancer Ther. 2005 Mar;4(3):427-34._x000D_ 10: Shi LF, Wu Y, Li CY. Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library J Gynecol Oncol. 2015 Oct;26(4):327-35. _x000D_ _x000D_ Products Related to Human Recombinant VEGFR3 Extracellular Domain can be found at Proteins

• Short Description:

  Catalog Number: B2017052 (50 µg)_x000D_ Human Recombinant VEGFR3 Extracellular Domain is a high quality protein that plays a key role in the regulation of lymphangiogenesis, the formation of lymphatic vessels. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3